论文部分内容阅读
目的检测再生障碍性贫血患者血清中血管内皮生长因子(VEGF)与表皮生长因子(EGF)的浓度,探讨VEGF和EGF在再生障碍性贫血患者血液中的表达及二者之间的关系和意义。方法应用酶联免疫技术(ELISA法)检测20例再障患者及40名健康人血清中VEGF和EGF浓度。结果20例再生障碍性贫血患者血清VEGF的含量为50.5±34.8pg/ml,对照组血清VEGF的含量为108.5±50.6pg/ml,两组比较有统计学意义(P<0.05)。20例再生障碍性贫血患者血清EGF含量为0.15±0.11μg/L,40例正常对照组血清EGF含量为0.76±0.80μg/L。结论再生障碍性贫血患者血清VEGF、EGF浓度显著低于健康对照组,且二者呈显著正相关。
Objective To detect the serum concentrations of vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF) in patients with aplastic anemia and to explore the relationship between the expression of VEGF and EGF in the blood of patients with aplastic anemia and their relationship. Methods Serum levels of VEGF and EGF were detected by enzyme-linked immunosorbent assay (ELISA) in 20 patients with aplastic anemia and 40 healthy individuals. Results The serum level of VEGF in 20 patients with aplastic anemia was 50.5 ± 34.8pg / ml, while the level of serum VEGF in control group was 108.5 ± 50.6pg / ml. There was significant difference between the two groups (P <0.05). The serum EGF level of 20 patients with aplastic anemia was 0.15 ± 0.11μg / L, and the serum EGF level of 40 normal controls was 0.76 ± 0.80μg / L. Conclusion Serum levels of VEGF and EGF in patients with aplastic anemia were significantly lower than those in healthy controls, and both were significantly and positively correlated.